Circulating tumor cells in advanced non-small cell lung cancer patients are associated with worse tumor response to checkpoint inhibitors

BACKGROUND: Non-small cell lung cancer (NSCLC) patients treated with checkpoint inhibitors show long lasting responses, but it is hard to predict which patients will profit from this treatment with the currently used marker, programmed death ligand 1 (PD-L1). We hypothesized that circulating tumor c...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Immunother Cancer
Autori principali: Tamminga, Menno, de Wit, Sanne, Hiltermann, T. Jeroen N., Timens, Wim, Schuuring, Ed, Terstappen, Leon W. M. M., Groen, Harry J. M.
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2019
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6617698/
https://ncbi.nlm.nih.gov/pubmed/31291995
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-019-0649-2
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi